Related Experiment Video
Updated: Jan 28, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
Medications for Early Life Epilepsy: Evidence Versus Experience?
Insights
Levetiracetam may be more effective than phenobarbital for treating infantile epilepsy. This study found levetiracetam led to better outcomes in infants with nonsyndromic epilepsy, suggesting a potential preferred treatment option.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Pharmacology
Background:
- Over half of infants with new-onset epilepsy present with nonsyndromic epilepsy, lacking defined electroclinical features.
- Levetiracetam and phenobarbital are common first-line treatments for infantile epilepsy, but their comparative effectiveness is not well-established.
Purpose of the Study:
- To compare the effectiveness of levetiracetam versus phenobarbital as initial monotherapy for infants diagnosed with nonsyndromic epilepsy.
Main Methods:
- A prospective, multicenter observational cohort study involving 155 infants with nonsyndromic epilepsy.
- Exposures included initial monotherapy with either levetiracetam or phenobarbital.
- The primary outcome was freedom from monotherapy failure at 6 months, defined by sustained seizure freedom and absence of additional antiepileptic drugs.
Main Results:
- Levetiracetam treatment was associated with a significantly higher rate of freedom from monotherapy failure compared to phenobarbital (40.2% vs 15.8%, P = .01).
- This superiority was maintained after adjusting for demographic, epilepsy, and neurological factors, as well as selection bias.
- The adjusted odds ratio for levetiracetam's effectiveness was 4.2 (95% CI, 1.1-16).
Conclusions:
- Levetiracetam demonstrates potentially superior effectiveness compared to phenobarbital for the initial monotherapy of nonsyndromic epilepsy in infants.
- These findings suggest levetiracetam may be a more effective first-line treatment option.
- Further randomized clinical trials are warranted to confirm these results.
Abstract:
Comparative Effectiveness of Levetiracetam vs Phenobarbital for Infantile Epilepsy Grinspan ZM, Shellhaas RA, Coryell J, Sullivan JE, Wirrell EC, Mytinger JR, Gaillard WD, Kossoff EH, Valencia I, Knupp KG, Wusthoff C, Keator C, Ryan N, Loddenkemper T, Chu CJ, Novotny EJ Jr, Millichap J, Berg AT. JAMA Pediatr. 2018 Apr 1;172(4):352-360. doi: 10.1001/jamapediatrics.2017.5211.
Importance:
More than half of infants with new-onset epilepsy have electroencephalographic and clinical features that do not conform to known electroclinical syndromes (ie, nonsyndromic epilepsy). Levetiracetam and phenobarbital are the most commonly prescribed medications for epilepsy in infants, but their comparative effectiveness is unknown.
Objective:
To compare the effectiveness of levetiracetam versus phenobarbital for nonsyndromic infantile epilepsy.
Design, Setting, And Participants:
The Early Life Epilepsy Study-a prospective, multicenter, observational cohort study conducted from March 1, 2012, to April 30, 2015, in 17 US medical centers-enrolled infants with nonsyndromic epilepsy and a first afebrile seizure between 1 month and 1 year of age. Exposures: Use of levetiracetam or phenobarbital as initial monotherapy within 1 year of the first seizure. Main Outcomes and Measures: The binary outcome was freedom from monotherapy failure at 6 months, defined as no second prescribed antiepileptic medication and freedom from seizures beginning within 3 months of initiation of treatment. Outcomes were adjusted for demographics, epilepsy characteristics, and neurologic history, as well as for observable selection bias using propensity score weighting and for within-center correlation using generalized estimating equations.
Results:
Of the 155 infants in the study (81 girls and 74 boys; median age, 4.7 months [interquartile range, 3.0-7.1 months]), those treated with levetiracetam (n = 117) were older at the time of the first seizure than those treated with phenobarbital (n = 38; median age, 5.2 months [interquartile range, 3.5-8.2 months] vs 3.0 months [interquartile range, 2.0-4.4 months]; P < .001). There were no other significant bivariate differences. Infants treated with levetiracetam were free from monotherapy failure more often than those treated with phenobarbital (47 [40.2%] vs 6 [15.8%]; P = .01). The superiority of levetiracetam over phenobarbital persisted after adjusting for covariates, observable selection bias, and within-center correlation (odds ratio, 4.2; 95% confidence interval [CI], 1.1-16; number needed to treat, 3.5 [95% CI, 1.7-60]).
Conclusions And Relevance:
Levetiracetam may have superior effectiveness compared to phenobarbital for initial monotherapy of nonsyndromic epilepsy in infants. If 100 infants who received phenobarbital were instead treated with levetiracetam, 44 would be free from monotherapy failure instead of 16 by the estimates in this study. Randomized clinical trials are necessary to confirm these findings.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:41A Pipeline for 3D Multimodality Image Integration and Computer-assisted Planning in Epilepsy Surgery
Published on: May 20, 2016
Related Concept Videos
The Evidence for Evolution
Half-life of a Reaction
Characteristics of Life
The Angiosperm Life Cycle
The Tree of Life - Bacteria, Archaea, Eukaryotes
The Stanford Prison Experiment